Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades and has been accepted as an effective therapeutic modality in the treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs) or neuroendocrine tumors (NETs). The two most commonly used radiopeptides for PRRT, 90Y-octreotide and 177Lu-octreotate, produce disease-control rates of 68%-94%, with progression-free survival rates that compare favorably with chemotherapy, somatostatin analogues, and newer targeted therapies.

Source: Seminars in Nuclear Medicine - April 9, 2016 Category: Nuclear Medicine Authors: Lisa Bodei, Dik J. Kwekkeboom, Mark Kidd, Irvin M. Modlin, Eric P. Krenning Source Type: research